For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 2,815 | |||
| General and administrative | 9,280 | |||
| Impairment loss on other intangible assets | 5,180 | |||
| Total operating expenses | 17,275 | |||
| Loss from operations | -17,275 | |||
| Interest income | 1 | |||
| Interest expense | 949 | |||
| Gain on settlement of current liabilities | 2,984 | |||
| Loss on debt extinguishment | -3,164 | |||
| Change in fair value of warrant liabilities | 775 | |||
| Loss on derivative liability | -230 | |||
| Foreign currency exchange gains (losses), net | -443 | |||
| Total other income, net | -1,026 | |||
| Net loss before income taxes | -18,301 | |||
| Income tax benefit | -1,003 | |||
| Net loss | -17,298 | |||
| Foreign currency translation adjustment | -44 | |||
| Total other comprehensive income, net of tax | -44 | |||
| Total comprehensive loss | -17,342 | |||
| Basic EPS | 0 | |||
| Diluted EPS | 0 | |||
| Basic Average Shares | 67,328,128,638 | |||
| Diluted Average Shares | 67,328,128,638 | |||
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)